# Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

> **NCT01527370** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 250 (actual)

## Conditions studied

- Herpes Zoster
- Shingles

## Interventions

- **BIOLOGICAL:** Zoster Vaccine Live

## Key facts

- **NCT ID:** NCT01527370
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-31
- **Primary completion:** 2013-04-09
- **Final completion:** 2013-04-09
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527370, "Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT01527370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*